Introduction 77
The gene encoding the growth hormone releasing hormone receptor (GHRHR) 78 is 15.51kb in length and incorporates 13 exons on chromosome 7p14. It encodes a G-79 protein coupled receptor (423aa) and is expressed on the somatotroph cells of the 80 anterior pituitary (1) . Its ligand growth hormone releasing hormone (GHRH), released 81 from the hypothalamus, stimulates the synthesis and release of growth hormone (GH; 82 encoded by GH1) upon binding in the presence of the pituitary-specific transcription 83 factor POU1F1 (PIT1) (2,3). GH in turn binds to receptors on the liver and generates 84 insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 85 (IGFBP3), thereby promoting growth. 86
Consistent with their role in growth regulation, mutations in GHRHR, GH1 87 and SOX3 are implicated in the etiology of isolated growth hormone deficiency 88 (IGHD) (4), and the pathway was recently implicated in the GHD phenotype observed 89 in the autosomal dominant disorder pseudohypoparathyroidism type 1b (5). 90
Autosomal recessive mutations occurring in the GHRHR gene have been implicated 91 in severe IGHD Type 1B, also known as Sindh dwarfism (6,7). Reported aberrations 92 in GHRHR have included missense, splice (8), nonsense (9,10), microdeletion and 93 promoter mutations (11, 12) . Many have been shown to specifically affect cAMP 94 production, for example GHRHR (p.K329E), which fails to show a cAMP response 95 after treatment with GHRH (13). All mutations described to date have shown a 96 complete loss of function. 97
Severe IGHD Type 1B was initially described in pedigrees from the Indian 98 subcontinent (14) and Brazil (15) . Interestingly the phenotype is usually not that of 99 classic IGHD in that affected patients have minimal facial hypoplasia and no resonance imaging (MRI) (3). However, growth failure is severe with proportionate 102 dwarfism and pubertal delay, and biochemically, the patients have low GH and IGF1 103 concentrations with otherwise normal pituitary function. To date, reported height in 104 untreated patients with a GHRHR mutation is on average 130 ± 10cm (-7.2 ± 1.6SDS) 105 in males and 114 ± 0.7cm (-8.3 ± 0.1SDS) in females (16). 106
Previous studies in our cohort of IGHD patients (n=224) revealed GHRHR 107 mutations in 3.7% of cases (15 patients from 7 pedigrees). All were familial cases, 108 predominantly from the South East Asian community, manifesting severe growth 109 failure with the vast majority showing APH on their MRI (7). In this manuscript, we 110 report the presence of two homozygous variants in GHRHR in consanguineous 111 pedigrees with a relatively mild GHD phenotype, and present functional data that 112 reveal the first partial loss of function mutation in GHRHR. Additionally, an 113 independent patient with the identical variants was also identified, suggesting the 114 
Molecular modelling 141
The RasMol prediction model database was used to build a 3D annotated 142 model of the GHRHR wild type and mutant proteins respectively, to analyse and 143 compare protein folding and structure. 144 stimulation test showed normal testosterone responses (11.1 nmol/l and 18.7 nmol/l respectively), with baseline gonadotrophins in the prepubertal range (LH <0.7U/L, 202 FSH 1.7U/L); both testes were visualised in the inguinal canal. By the age of 2 years, 203 he had a further 6-week hCG treatment course with good response in terms of 204 testicular descent. However, at the age of 4 years, he had left testicular torsion with 205 subsequent orchidectomy and right orchidopexy. By the age of 6 years his height was 206 110.2 cm (-1.21 SDS) and his growth velocity had slowed to 3.6cm/year (-2.63 SDS) 207 ( Figure 2B ). Glucagon stimulation test at that time confirmed GHD with a peak GH 208 of 2.9µg/l and a low IGF1 (18 ng/ml; normal range (NR) 45-321 ng/ml) and IGFBP3 209 (1.24 mg/l; range 1.86-4.39) ( Table 2) Biochemical testing revealed GH deficiency, with a peak GH to glucagon testing of 235 1.1µg/l, an IGF1 of 17 ng/ml (NR 45-321 ng/ml) and an IGFBP3 of 1.52 mg/L (NR 236 1.862-4.399 mg/L) ( Table 2) . At the age of 6 years she failed to respond to a GHRH 237 test, and was subsequently commenced on rhGH treatment at a dose of 238 0.65mg/m 2 /day ( Figure 2C ). She underwent spontaneous puberty and there were no 239 concerns regarding her physical development. She has achieved a final height of 166 240 cm (+0.66 SDS) ( Table 1) . Her father's cousin has two daughters that are on GH 241 treatment for short stature (DNA not available). 242 243
Mutational analysis 244
Following direct sequencing analysis of three siblings (pedigree I) and an 245 unrelated female patient (pedigree II) with IGHD, two homozygous variants were 246 identified in the GHRHR gene in all four patients. The first was a novel homozygous 247 missense variant in exon 1 (c.11G>A) (Figure 1Ci in complex with the extracellular domain of its receptor (likely to have the same 264 structure as the GHRHR extracellular domain) shows that residues close to p.P79 265 interact with the ligand. Therefore, even if the mutant protein were to fold correctly 266 without the disulphide bond in place (or with a weak disulphide bridge), the mutation 267 is still predicted to disrupt the ligand-binding region. 268
It was not possible to model the R4Q mutant as the model did not extend far 269 enough into the N-terminus. This region is in the signal peptide and is outside the 270 hydrophobic region shown to be required for function (17). Additionally, the arginine 271 or glutamine at position 4 (p.R4Q) have identical scores for signal peptide prediction 272 (SignalIP4.1). 273
Functional analysis was performed by monitoring cAMP responses of cells 276
expressing wild-type and mutant GHRHR to varying concentrations of GHRH, and 277 demonstrated that the double p.R4Q/p.P79L mutation had a significantly reduced 278 maximal activity to 52.0+/-4.6% of wild-type GHRHR (p<0.001; Figure 3) , with a 279 reduction in affinity for the GHRH1-44 ligand (EC50 p.R4Q/p.P79L 113x10 -11 +/-280 1.51x10 -11 vs WT 1.12x10 -11 +/-0.21x10 -11 , p<0.001). Analysis of GHRHR protein 281 with individual mutations demonstrated that p.P79L is responsible for both the 282 reduction in activity (55.3+/-4.4% of wild-type, p<0.001) and the altered affinity 283 (EC50 113x10 -11 +/-1.51x10 -11 , p<0.001 vs WT; non-significant difference vs 284 p.R4Q/pP79L) ( Figure 3 ). The single p.R4Q mutation had no significant effect on 285 either maximal activity (p = 0.65) or EC50 (p = 0.9) compared with wild type 286 GHRHR (Figure 3 The asymptomatic mother of patients IV.1-IV.3 was a heterozygous carrier of 310 both variants, and the father is also expected to be a carrier, although his DNA is 311 unavailable. The presence of these two homozygous variants in the two ostensibly 312 unrelated families raises the possibility that pedigrees I and II are distantly related or 313 may originate from the same area in South-East Asia. 314
Apart from a single report (18), patients with GHRHR mutations do not have 315 neonatal hypoglycemia and in all reports to date they are reported to have normal 316 genitalia. This is the first report of male patients with GHRHR mutations presenting 317 with a micropenis and bilateral undescended testes. The mechanism underlying this 318 presentation is unknown. 319 A number of previously reported missense GHRHR mutations (p.H137L, 320 p.L144H, p.A176V, p.A222E, p.F242C, p.K329E) have been shown to result in 321 correct surface expression of the receptor but reduced ability to bind to GHRH, 322 thereby impairing intracellular signalling and stimulation of GH secretion (19, 13, 20) . 323
However, a missense mutation (p.V10G) within the signal peptide has been shown to 324 affect the correct processing of the receptor and results in incomplete cleavage of the signal peptide with failure of the mutant GHRHR receptor to translocate to the cell 326 surface (17). The first variant, p.R4Q in exon 1, results in the substitution of a 327 strongly basic arginine residue by a neutral glutamine residue. Despite our p.R4Q 328 variant being located in the signal peptide, when arginine is substituted by tryptophan 329 (p.R4W) at position 4 there is unaltered function, and this is consistent with our 330 functional data whereby the p.R4Q variant appears to retain function (17). 331
The second variant, p.P79L in exon 3 results in the substitution of a proline 332 residue by leucine. Proline is known to be essential for protein folding (21); therefore 333 its loss at this highly conserved position will likely affect protein conformation, which 334 supports our protein prediction model for p.P79L. The functional assays performed 335 further support this and conclude that the p.P79L mutation alters the binding affinity 336 and activity of GHRHR, and is thus the likely cause of the GHD observed in patients 337 IV.1-IV.3 and II.1. Therefore the 50% reduction in the maximal cAMP response to 338 stimulation with GHRH observed by the p.R4Q/p.P79L double mutant receptor is 339 most likely due to this pathogenic p.P79L mutation alone rather than the combination 340 of both p.R4Q and p.P79L (Figure 3 ). Our studies do not rule out the possibility that 341 the p.R4Q variant may be contributory in some way to the mild phenotype. 342 343
Conclusion 344
We report the presence of two novel homozygous variants in GHRHR in a 345 pedigree, and an unrelated patient with IGHD, suggesting a possible founder effect of 346 these variants in patients with IGHD originating from a certain area of South-East 347
Asia. The initial phenotype of all patients appears to be relatively mild, despite the 348 presence of the two variants in the same gene. We show here the importance of 349 performing functional studies in this highly unusual scenario where two variants are Table Table 2 .docx Figure Figure 3 .tif
